Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndromeFeng Xu, Liyu Zhou|Scientific Reports|2014Cited by 49
Interleukin‐17 enhances the production of interferon‐γ and tumour necrosis factor‐α by bone marrow <scp>T</scp> lymphocytes from patients with lower risk myelodysplastic syndromesZheng Zhang, Chunkang Chang, Juan Guo et al.|European Journal Of Haematology|2013Cited by 36
Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndromeFeng Xu, Xiao Li|Oncotarget|2016Cited by 34
DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromesNanfang Huang, Feng Xu|iScience|2023Cited by 9